Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Homologous Third Dose of Covid-19 Vaccine (Fiocruz/AstraZeneca)
NCT05142488Phase 4Unknown
- Sponsor
- Immunobiological Technology Institute
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Immunobiological Technology Institute. Primary endpoint: IgG Anti-S response after a third dose at 28 days. Status: unknown.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05142488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142488.